

Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment

Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced that the company's shares will be moved to Nasdaq Stockholm's Mid Cap segment on January 3rd, 2022.

The move from the Small Cap segment is a result of Nasdaq's annual review of the average market values within the Nordic market segments. The Mid Cap segment includes companies with a share value between EUR 150 million and EUR 1 billion. The move was announced by Nasdaq Stockholm on December 20th, 2021. The company is now taking the step from the Small Cap to the Mid Cap segment after a strong price trend during the year.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.3bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally four biosimilar candidates in its pipeline targeting € 24.3bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.

For more information, visit www.xbrane.com.

Attachments

[Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment](#)